Physician profile
Richard E Ferraro
NPI 1376598508
$1,377.84
in general payments reported to CMS, 2019-2025
11 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $22.44 · 2021: $104 · 2022: $208 · 2023: $154 · 2024: $477 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $296.20 | 2019-2025 | |
| Aerin Medical INC. | $266.92 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $210.91 | 2021-2025 | Dupixent |
| Medtronic, INC. | $160.10 | 2021-2024 | Nuvent, Propel |
| Alk-Abello, INC | $138.64 | 2019 | |
| Glaxosmithkline, LLC. | $98.68 | 2022-2025 | Nucala |
| Genzyme Corporation | $82.69 | 2023-2025 | |
| Neurent Medical Limited | $60.76 | 2022 | |
| Kaleo, INC. | $26.15 | 2021 | |
| Stryker Corporation | $20.09 | 2019 | |
| Hikma Pharmaceuticals USA | $16.70 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ferraro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.